Danaher sees Q1 base business core revenue up mid-single digits

Consensus $7.36B. Starting with the first quarter, the company will revise its definition of base business core growth to exclude revenues related to COVID-19 testing, vaccines and therapeutics, in addition to the exclusion of currency translation, acquisitions and divested product lines. For the first quarter, the company anticipates that non-GAAP base business core revenue growth will be up mid-single digits. Blair continued, "Looking ahead, we believe the combination of our leading portfolio, the power of the Danaher Business System and the strength of our balance sheet position Danaher to continue generating sustainable, long-term shareholder value for many years to come."